Effect and safety of subcutaneous semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in subjects with overweight or obesity Save

Date Added
September 18th, 2019
PRO Number
Pro00091527
Researcher
Patrick O'neil

List of Studies


Profiles_link
Keywords
Drug Studies, Obesity, Weight Control
Summary

This is a 76-week trial comparing semaglutide 2.4 mg taken once weekly with liraglutide 3.0 mg taken once daily as an adjunct to a reduced-calorie diet and increased physical activity in subjects with overweight or obesity . This is a randomized, double-blinded trial. Each active medication will be compared against a placebo and be administered per a dosing schedule.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

Change_preferences

-- OR --

Create_login